



Universiteit
Leiden

The Netherlands

How T cells talk to the neighborhood: the spatiotemporal dynamics of T cell-derived cytokines in cancer

Hoekstra, M.E.

Citation

Hoekstra, M. E. (2023, April 6). *How T cells talk to the neighborhood: the spatiotemporal dynamics of T cell-derived cytokines in cancer*. Retrieved from <https://hdl.handle.net/1887/3590479>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3590479>

Note: To cite this publication please use the final published version (if applicable).

6

Modulation of the tumor micro-environment by CD8⁺ T cell-derived cytokines

Mirjam E. Hoekstra, Saskia V. Vijver and Ton N. Schumacher

Current Opinion in Immunology, 2021.

DOI: [10.1016/j.coi.2021.03.016](https://doi.org/10.1016/j.coi.2021.03.016)

Abstract

Upon their activation, CD8⁺ T cells in the tumor micro-environment (TME) secrete cytokines such as IFN γ , TNF α , and IL-2. While over the past years a major interest has developed in the antigenic signals that induce such cytokine release, our understanding of the cells that subsequently sense these CD8⁺ T-cell secreted cytokines is modest. Here, we review the current insights into the spreading behavior of CD8⁺ T-cell-secreted cytokines in the TME. We argue for a model in which variation in the mode of cytokine secretion, cytokine half-life, receptor-mediated clearance, cytokine binding to extracellular components, and feedback or forward loops, between different cytokines or between individual tumors, sculpts the local tissue response to natural and therapy-induced T-cell activation in human cancer.

Introduction

CD8⁺ cytotoxic T lymphocytes (CTLs) play a central role in immune-mediated control of cancer^{1,2}. Upon tumor cell recognition, CTLs release cytotoxic granules toward their target via the immune synapse (IS)¹. In parallel, activated CTLs secrete cytokines, such as interferon γ (IFN γ), tumor necrosis factor α (TNF α) and interleukin-2 (IL-2), which can, on their own or jointly, modify the behavior of cells carrying the corresponding cytokine receptors. The effects of cytokine receptor signaling on the tumor micro-environment (TME) are highly diverse, and include immune cell activation, regulation of antigen presentation and immune checkpoint molecules, and, in some cases, the induction of tumor cell senescence and death^{3,4,5}. Notably, pre-clinical and clinical studies have provided evidence for both positive and negative effects of IFN γ , TNF α and IL-2 signaling on tumor control^{3,4,5,6,7,8,9,10,11,12}. One major factor that drives this differential effect is likely to be formed by context-dependent differences in the outcome of cytokine receptor signaling. However, an entirely independent factor that may influence the response of tumors to cytokine secretion could be the extent to which cytokines are able to spread in the TME or, in other words, which cells and how many cells can actually sense such cytokine secretion. Here we discuss the factors that influence the spreading of CD8⁺ T cell-secreted cytokines within the TME and propose that variation in such factors can form a determinant of the response of individual tumors to T-cell activity.

Spatiotemporal behavior of CD8⁺ T cell-secreted cytokines

Cytokines can, at least in some cases, spread substantial distances in (tumor) tissue micro-environments. Indirect evidence for this notion is, for example, provided by the observation that in mouse models, the effects of IFN γ and TNF α on endothelial cells can be critical for tumor control¹³ while these cells may be less likely to be directly recognized by T cells. Secondly, the observed role of cytokine receptor signaling in resistance to immune checkpoint blockade^{7,9,10,14} is also suggestive of a more widespread effect of T cell-secreted cytokines. For example, if the impaired IFN γ receptor (IFN γ R) signaling that has been observed in α PD-1 resistant lesions would lead to tumor resistance by reducing the level of antigen presentation, this could only be expected to provide a selective advantage to cells that aren't already being recognized by T cells. Finally, computational models have also led to a model in which cytokine diffusion gradients are invoked to explain the tumor control that is observed at low T-cell densities¹⁵.

Direct evidence for long distance cytokine spreading comes from a small set of *in vivo* mouse studies that analyzed tissue effects of TNF α , IL-2, and in particular IFN γ . For example, T cell-secreted IFN γ in skin and lymphoid tissues has been shown to induce expression of IFN γ -responsive genes in large areas outside parasite or virus infected regions^{16, 17, 18, 19}. By the same token, the production of IFN γ and TNF α by intratumoral CD4⁺ T cells has been shown to induce senescence in tumor cells that are deficient for MHC class II, and that can thus not be directly recognized by these T cells²⁰. In recent work, the spreading of CTL-secreted IFN γ has been quantified in mouse tumor models. Using mosaic tumors containing both antigen-positive and antigen-negative 'bystander' tumor cells, it was shown that a large fraction of bystander cells does undergo productive IFN γ R signaling. Such sensing of CTL-secreted IFN γ was observed for bystander cells at distances over hundreds of micrometers (>100 μ m [21*] >800 μ m^{22*}) from sites of T-cell activation, as revealed by, for instance, the expression of MHC-I and PD-L1 molecules, or the induction of cell death^{21*,22*}. While the abovementioned data were obtained in immunogenic transplantable tumor models, and in one case lacking endogenous IFN γ R-positive cells^{22*}, qualitatively comparable conclusions can be drawn from studies that analyzed cytokine distributions in tissues such as skin and lymph nodes^{16, 17, 18, 19}.

The extent to which cytokine secretion induces receptor signaling in distant cells is determined by both the degree of cytokine spreading from the producing cells, and the threshold of the receiver cells to initiate signal transduction. Here, we focus on the

first of these components, distinguishing five parameters that have been proven, or are expected, to influence the spatial spreading of cytokines: the mode of cytokine secretion, cytokine half-life (including aspects such as biochemical stability and proteolytic (in) activation), receptor-mediated clearance, binding to extracellular components, and feedback/feedforward loops (Figure 1 and Table 1). Jointly, these factors determine how a pool of secreted cytokine molecules is distributed over the TME.




Figure 1. Potential factors affecting cytokine spreading in the TME.

The spatiotemporal behavior of CD8⁺ T cell cytokines is likely to depend on (a) the mode of cytokine secretion by the producing cell, and (b) environmental factors influencing receptor-mediated clearance, cytokine half-life, cytokine binding to extracellular components, and feedback/feedforward loops. Variation between these factors is expected between tumors, due to, for example, their genetic make-up, immune infiltrate, molecular ECM structure, level of hypoxia, and nutrient availability.

Table 1. Factors shown or expected to influence the spreading behavior of CD8⁺ T-cell-secreted cytokines within the TME.

| | Cytokine | Observation | References |
|--|-----------------|--|-----------------------------|
| Mode of secretion | IFN γ | Synaptic release (in vitro) | 24, 25, 26 |
| | TNF α | Multidirectional release (in vitro) | 25 |
| | IL-2 | TACE-mediated cleavage of transmembrane TNF α (in vitro) Synaptic release (in vitro) | Reviewed in Ref. 38 25 |
| Biochemical stability and proteolytic cleavage | IFN γ | Increased half-life by HS/heparin-mediated prevention of inactivating proteolytic cleavage (in vitro) | 32,33* |
| | TNF α | Activating cleavage up to ten C-terminal amino acids (facilitated by HS/heparin-binding) (in vitro) Instable trimers after membrane cleavage (in vitro) | 32,33* 41 |
| Receptor-mediated clearance | IFN γ | Receptor expression modulation by internal and environmental factors such as TNF α and IL1 β (in vitro) | 27,38 |
| | TNF α | TNFR1 and TNFR2 are expressed on distinct cell types and differ in their affinity to TNF α (in vitro/in vivo) TACE-mediated cleavage of TNFRs (in vitro) | Reviewed in Ref. 42 46 |
| | | Low, intermediate, and high affinity IL-2 receptor variants, expressed by distinct cell types (in vivo) | Reviewed in Ref. 12 |
| | IL-2 | Receptor expression modulated by FoxP3 and TCR signaling (in vitro) IL-2 spreading distance is influenced by the size of the Treg pool (in vitro, suggestive in vivo) | Reviewed in Ref. 12 51** |
| | | Shedding of the IL-2R α chain mediated by tumor-cell derived metalloproteinases or as a result of T-cell activation (in vitro) | 53,54 |
| Receptor-independent capture | IFN γ | PS-mediated catch and release by tumor cells (in vitro) Galectin-3 mediated containment within the TME (in vivo) | 29** 31** |
| | | HS- or heparin-binding of IFN γ (in vitro) Restricted spreading into tissues following heparin IV. injection (in vivo) | Reviewed in Ref. 33* 34 |
| | TNF α | Binding to biglycan, decorin, dermatan sulfate, fibronectin and laminin (in vitro) | 43, 44, 45 |
| | IL-2 | Binding to galectin-3, collagen and HS/heparin (in vitro) | 31** ,56,57 |
| Loops | IFN γ | IFN γ -induced IFN γ production in antigen-stimulated CD4 ⁺ T cells (in vitro) | 35 |
| | TNF α | TNF α stimulation increases sTNFR levels (in vitro) | 47 |
| | IL-2 | IL-2 induced expression of IL-2R (in vitro) Inhibition of IL-2 production upon IL-2R signalling (in vitro) | 52 55 |

IFN γ

Of all CTL derived cytokines, the spatial dynamics of IFN γ have been characterized most extensively. CD8⁺ T cells start secreting IFN γ molecules within minutes to hours after T-cell receptor (TCR) triggering²³. Continued secretion appears to be highly dependent on active TCR stimulation^{22*,23}, and substantial spreading of IFN γ is therefore unlikely to occur because of continued production by T cells after target cell dissociation. There

is compelling evidence that IFN γ secretion by CTLs is specifically directed toward the synapse that is formed with the antigen-positive target cell²⁴. While it has been suggested that this directional mode of secretion would result in selective delivery of IFN γ to the target cell²⁵, studies demonstrating IFN γ effects on bystander cells^{18,19,21,22,24,26} argue against such a 'target cell only' model. It remains to be determined whether this apparent discrepancy is explained by leakiness of the synapse, unnoticed multidirectional secretion of IFN γ , or release of unconsumed IFN γ into the environment at the moment the synapse is dismantled.

The IFN γ R is expressed on all nucleated cells³, allowing binding of IFN γ to immune cells, tumor cells and stromal cells in the TME. While formal evidence is lacking, the large pool of receptors available for binding makes it plausible that receptor-mediated clearance forms an important determinant in IFN γ spreading. Notably, IFN γ R receptor expression can be modulated by both internal factors and by environmental cues, such as TNF α and IL1 β ^{27,28}, conceivably influencing the magnitude of receptor-mediated clearance and hence IFN γ spreading. Besides IFN γ R-mediated clearance, there is evidence that IFN γ capture by cell membrane proteins or extracellular matrix (ECM) components present in the TME influences the spatiotemporal behavior of IFN γ . For example, recent work has indicated that the binding of IFN γ to Phosphatidyl Serine (PS), a phospholipid over represented on the outside of viable tumor cells and dead cells, results in the capture of IFN γ molecules by tumor cells and their subsequent slow release, thereby allowing delayed receptor binding and signaling. This process of IFN γ detainment is likely dependent on the pronounced positively charged surface area of IFN γ , a property shared with cytokines such as IL-12 and IL-23, but not TNF α or IL-2²⁹. In addition, binding of IFN γ to ECM components has been shown to influence its distribution in the TME. For example, galectins, (tumor-)cell secreted ECM proteins that form supramolecular complexes, have been shown to trap cytokines in the TME³⁰. Specifically, recent work has demonstrated that following intratumoral IFN γ injection, galectin-3 reduces IFN γ diffusion through the tumor matrix, as read out by the fraction and location of cells expressing the IFN γ inducible CXCL9 chemokine in the presence or absence of a galectin antagonist³¹. Next to galectins, the ECM glycosaminoglycans heparin and heparan sulfate (HS) are likely to influence the spatiotemporal behavior of IFN γ . Specifically, *in vitro* data has demonstrated that IFN γ binding to heparin and HS can increase IFN γ half-life by preventing inactivating proteolytic cleavage³². In addition, HS binding can also facilitate partial proteolytic cleavage, resulting in truncated IFN γ molecules with increased activity³³. While the relevance of HS or heparin binding to IFN γ within tumor

lesions remains to be established, heparin has been shown to restrict spreading of IFN γ into tissues following I.V. injection ³⁴. Finally, IFN γ R signaling may in certain settings induce the expression of IFN γ . Although thus far only reported for antigen-stimulated CD4⁺ T cells in *in vitro* assays ³⁵, such direct feedforward loops could potentially have a major impact on the spatiotemporal distribution of cytokines. For example, the observed sensing of IFN γ by tumor cells that are far removed from T-cell activation sites ^{21*,22*} could in part be due to a self-propagating process in which cells instruct neighboring cells to also become cytokine producers. As a side note, should such T cell-based positive feedback loops exist in tumor microenvironments, this may imply that T cells that are considered ‘bystanders’ based on their antigen specificity ³⁶ could nevertheless fulfill an important role in tumor control. Conceivably, nonlymphoid cells such as macrophages, monocytes and dendritic cells may also contribute to such an IFN γ feedforward loop, as IFN γ sensing by these cells leads to increased expression of T-bet, a transcription factor that controls IFN γ expression ^{35,37}.

TNF α

At present, little is known regarding the *in vivo* spreading of TNF α and we can therefore only provide an incomplete view, based on information obtained in *in vitro* assays. Following T-cell activation, translation of preformed TNF α mRNA is induced, leading to the production of a trimeric membrane protein that is subsequently transported to the cell membrane ^{38,39}. In contrast to IFN γ and IL-2, TNF α is not targeted towards the IS, but distributed equally over the cell membrane, as shown by live imaging of TNF α on activated murine CD4⁺ T cells ²⁵. Membrane bound TNF α (mTNF α) can subsequently be converted to soluble TNF α (sTNF α) through the action of TNF-alpha-converting enzyme (TACE) ³⁸. Interestingly, both mTNF α and sTNF α can signal through TNF α receptors (TNF α Rs), and it is likely that TNF α signal diffusion is to a certain degree regulated by the availability of TACE, which can be increased by T-cell activation ⁴⁰. The *in vitro* half-life of sTNF α is limited by its spontaneous conversion into inactive monomeric TNF α ⁴¹. Assuming that reassembly of trimeric sTNF α is unlikely at physiological TNF α concentrations, the intrinsic instability of TNF α may be an important factor determining the extent of its spreading. Trimeric TNF α can signal through both TNFR1 and TNFR2, but with receptor triggering resulting in distinct signaling outcomes. Specifically, signaling through the ubiquitously expressed TNFR1 is generally associated with cell death, although roles in inducing inflammation and proliferation have been described as well. In contrast, signaling through TNFR2, which is primarily expressed by tumor cells and immunosuppressive cells, mostly induces pro-survival, proliferative

and proinflammatory effects, and TNFR2 lacks the death-domain present in TNFR1^{38,42}. Interestingly, while TNFR1 strongly responds to both mTNF α and sTNF α , TNFR2 is primarily activated by mTNF α ⁴². Thus, if one assumes that soluble TNF α molecules may spread further within tumor micro-environments, the outcome of TNF α -induced signaling may show spatial heterogeneity. We do note though that, contrary to sTNF α , mTNF α may 'travel' in the tissue environment while still bound to a migrating producing cell, thereby increasing its reach. However, data on the relevance of such postulated travel in the cell-bound state are lacking.

The role of extracellular components in the tissue distribution of TNF α remains largely unexplored. Although binding of TNF α to biglycan, decorin, dermatan sulfate⁴³, fibronectin⁴⁴ and laminin⁴⁵ has been shown in *in vitro* experiments, the potential *in vivo* consequences of these interactions remain unclear. One class of molecules that has been suggested to be important for the regulation of TNF α activity *in vivo* comprises soluble TNF α receptors (sTNFR). *In vitro*, both TNFR1 and TNFR2 can be shed from the membrane through TACE-mediated cleavage⁴⁶, and stimulation of cells with TNF α has been shown to increase sTNFR levels⁴⁷. Knock-in mice that only express a mutated, non-sheddable TNFR1 show immune hyperreactivity, characterized by improved control of intracellular bacterial infections, but also severe inflammatory conditions⁴⁸. Conceivably, TNFR shedding may influence receptor signaling in two distinct ways, on the one hand reducing the number of receptors available for signaling, and on the other hand (temporarily) sequestering extracellular TNF α , potentially extending the duration of the TNF α response. In line with these data in preclinical models, germline mutations related to TNFR1 shedding have been linked to inherited autoinflammatory syndromes in humans⁴⁹. While the role of receptor shedding in the TME has not been well investigated, high levels of sTNFRs have been observed in cancer patients⁴², providing a rationale for further study.

IL-2

In contrast to IFN γ and TNF α , which can influence the behavior of almost all cells in the TME, the activity of IL-2 is mostly restricted to T cells¹². While it is well-established that IL-2 production is critical for CD8⁺ T-cell mediated tumor control^{12,50}, our understanding of IL-2 spreading is limited to *in vitro* data and *in vivo* analyses of CD4⁺ T cells in lymphoid organs. IL-2 is rapidly secreted into the IS by activated T cells²⁵. However, similar to what has been described for IFN γ , *in vitro* data demonstrating, and *in vivo* data suggestive of, IL-2 sensing by cells located many cell layers away from producing cells have been

obtained⁵¹. The IL-2 — IL-2 receptor (IL-2R) system forms a prime example of the regulation of cytokine sensing through the controlled expression of cytokine receptor variants. The IL-2R can exist in three configurations: a low affinity receptor consisting of the IL-2R α chain, a heterodimeric intermediate affinity IL-2R consisting of the γ and β chains, and a heterotrimeric high affinity receptor composed of the α , β and γ subunits¹². Expression of the IL-2R α chain, which is devoid of signaling capacity and can hence be viewed as an affinity regulator, is both regulated by cell type-specific transcription factors, such as FoxP3 in regulatory T cells (Tregs)¹², and by external signals, such as TCR triggering or IL-2R signaling⁵². Moreover, shedding of the IL-2R α chain, as a result of T-cell activation⁵³ or facilitated by tumor-cell derived metalloproteinases⁵⁴, can occur, forming an additional layer of IL-2R affinity regulation. The IL-2-induced expression of IL-2R α has elements of both a feedforward and a feedback loop. Specifically, while expression of the IL-2R α chain (and thereby the high-affinity IL-2 receptor) increases the sensitivity of an individual cell to cytokine, capture of IL-2 by the high affinity receptor and subsequent internalization can also diminish cytokine spreading. In addition, evidence for a second feedback loop has been obtained, in which IL-2 production is inhibited by IL-2R signaling⁵⁵, conceptually also resulting in a reduced IL-2 reach within tissues. Several studies have provided evidence that IL-2 can both suppress and enhance adaptive immune responses¹², likely depending on the distinct cells that consume it. Specifically, it has been suggested that Tregs, which constitutively express the high affinity α - β - γ receptor, and effector T cells, which only express the IL-2R α chain upon activation, compete for IL-2 depending on their relative distance to the IL-2 producing cells⁵². Consistent with the notion that receptor-mediated clearance forms a major factor in the regulation of IL-2 spreading from its site of production, artificial expansion of the Treg pool was shown to limit the distances between IL-2 producing and sensing cells⁵¹. Furthermore, mathematical modeling based on these data suggested that IL-2 spreading is primarily regulated through a tunable diffusion-consumption mechanism, without a significant role of factors such as directionality in cytokine secretion or cell movement⁵¹. It is noted that in this model, potential effects of binding of IL-2 to ECM components were not considered. However, as prior work has demonstrated binding of IL-2 to ECM collagens⁵⁶ and galectin-3³¹ in *in vitro* assays, and to HS and heparin *in vivo*⁵⁷, it is possible that ECM binding will form an additional factor influencing IL-2 sensing in the tumor micro-environment. It is plausible that IL-2R/Treg-based IL-2 consumption mechanisms are also relevant to human disease, as large numbers of Tregs⁵⁸, as well as high expression of IL-2R α by Tregs⁵⁹, have been observed in human cancers.

Conclusions and future directions

As discussed above, a number of factors in the TME can regulate the spatial distribution and sensing of cytokines within tumors. Importantly, clear heterogeneity between tumors for at least part of these variables has been observed, making it likely that cytokine spreading after T-cell activation will vary between individual tumors. For example, the amount and molecular structure of ECM components, such as galectin-3, heparin and HS molecules, varies strongly between tumors, depending on their genetic make-up, degree of hypoxia, nutrient availability, and cellular infiltrate^{60, 61, 62}. Additionally, variation in cytokine consumption potential may be inferred from the widely differing Treg numbers in human tumors^{58, 63}. Moreover, the levels and types of proteolytic enzymes, including TACE, have been demonstrated to differ substantially between tumors^{64, 65}, likely influencing the kinetics of cytokine degradation, receptor shedding or, in case of TACE, skewing signaling towards either TNFR₁ or TNFR₂. We note that it is conceivable that cancer treatments may also influence the degree of cytokine spreading. As one example, high levels of PS are expressed on the outer membrane of dying cells, potentially reducing the diffusion rate of IFN γ after cytotoxic therapies.

Which information would help to better understand the rules governing cytokine spreading in human cancers? An area of research that has only recently started to gain significant attention, is the relative contribution of the different mechanism that may regulate cytokine spreading and sensing^{66*}. An important source of information in such efforts may be the use of spatially resolved transcriptomics and proteomics, which would potentially allow one to measure the spatial relationship between cytokine-producing and sensing cells, and the effect of different parameters on this relationship. Finally, understanding how cytokine containment and spreading within local TMEs may be controlled will be necessary to optimally exploit this axis in therapeutic strategies.

References and recommended reading

Papers of particular interest, published within the period of review have been highlighted as:

* of special interest

** of outstanding interest

1. Durgeau A et al.: Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. *Front Immunol* 2018, 9:14.
2. Hadrup S, Donia M, Thor P: Straten, effector CD4 and CD8 T cells and their role in the tumor microenvironment. *Cancer Microenviron* 2013, 6:123-133.
3. Castro F et al.: Interferon-gamma at the crossroads of tumor immune surveillance or evasion. *Front Immunol* 2018, 9:847.
4. Montfort A et al.: The TNF paradox in cancer progression and immunotherapy. *Front Immunol* 2019, 10:1818.
5. Lim SO et al.: Deubiquitination and stabilization of PD-L1 by CSN5. *Cancer Cell* 2016, 30:925-939.
6. Zaretsky JM et al.: Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N Engl J Med* 2016, 375:819-829.
7. Shin DS et al.: Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. *Cancer Discov* 2017, 7:188-201.
8. Sucker A et al.: Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. *Nat Commun* 2017, 8:15440.
9. Gao J et al.: Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. *Cell* 2016, 167:397-404.e9.
10. Bertrand F et al.: TNF α blockade overcomes resistance to anti-PD-1 in experimental melanoma. *Nat Commun* 2017, 8:2256.
11. Vredevoogd DW et al.: Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold. *Cell* 2019, 178:585-599.e15.
12. Spolski R, Li P, Leonard WJ: Biology and regulation of IL-2: from molecular mechanisms to human therapy. *Nat Rev Immunol* 2018, 18:648-659.
13. Kammertoens T et al.: Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. *Nature* 2017, 545:98-102.
14. Grasso CS et al.: Conserved interferon-gamma signaling drives clinical response to immune checkpoint blockade therapy in melanoma. *Cancer Cell* 2020, 38:500-515.
15. Beck RJ, Slagter M, Beltman JB: Contact-dependent killing by cytotoxic T lymphocytes is insufficient for EL4 tumor regression in vivo. *Cancer Res* 2019, 79:3406-3416.
16. Ariotti S et al.: T cell memory. Skin-resident memory CD8(+) T cells trigger a state of tissue-wide pathogen alert. *Science* 2014, 346:101-105.
17. Schenkel JM et al.: T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. *Science* 2014, 346:98-101.
18. Perona-Wright G, Mohrs K, Mohrs M: Sustained signaling by canonical helper T cell cytokines throughout the reactive lymph node. *Nat Immunol* 2010, 11:520-526.
19. Muller AJ et al.: CD4+ T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen

- presentation. *Immunity* 2012, 37:147-157.
20. Braumuller H et al.: T-helper-1-cell cytokines drive cancer into senescence. *Nature* 2013, 494:361-365.
 21. Thibaut R et al.: Bystander IFN-gamma activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. *Nat Cancer* 2020, 1:302-314
 * Using intravital imaging and a reporter for STAT1 translocation, this paper demonstrates that CD8 + T-cell derived IFN γ diffuses extensively in mouse tumors to alter the tumor microenvironment in distant areas. Additionally, single-cell RNA-sequencing data from melanoma patients provide evidence that IFN γ R signaling also may occur in bystander cells in human tumors.
 22. Hoekstra ME et al.: Long-distance modulation of bystander tumor cells by CD8(+) T cell-secreted IFN γ . *Nat Cancer* 2020, 1:291-301
 * Using a GAS-based IFN γ sensing reporter and multiday intravital imaging of tumors in mice, this paper reveals sensing of CD8 + T-cell secreted IFN γ over large distances in tumor masses. The observed long-range sensing of IFN γ is also shown to modify the behavior of antigen-negative tumor cells, as demonstrated by both induction of PD-L1 expression and inhibition of tumor growth.
 23. Slifka MK, Rodriguez F, Whitton JL: Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. *Nature* 1999, 401:76-79.
 24. Sanderson NS et al.: Cytotoxic immunological synapses do not restrict the action of interferon-gamma to antigenic target cells. *Proc Natl Acad Sci U S A* 2012, 109:7835-7840.
 25. Huse M et al.: T cells use two directionally distinct pathways for cytokine secretion. *Nat Immunol* 2006, 7:247-255.
 26. Puntel M et al.: Identification and visualization of CD8+ T cell mediated IFN-gamma signaling in target cells during an antiviral immune response in the brain. *PLoS One* 2011, 6:e23523.
 27. Shirey KA et al.: Upregulation of IFN-gamma receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells. *J Interferon Cytokine Res* 2006, 26:53-62.
 28. Chen C et al.: Modulation of IFN-gamma receptor 1 expression by AP-2alpha influences IFN-gamma sensitivity of cancer cells. *Am J Pathol* 2012, 180:661-671.
 29. Oyler-Yaniv J et al.: Catch and release of cytokines mediated by tumor phosphatidylserine converts transient exposure into long-lived inflammation. *Mol Cell* 2017, 66:635-647.e7
 ** Combining mathematical modeling with various experimental approaches including a mouse model of thyroid cancer, this paper demonstrates that IFN γ is captured by phosphatidylserine on the surface of viable tumor cells in vivo, followed by its slow release to drive pro-longed transcription of IFN γ responsive genes.
 30. Gordon-Alonso M, Bruger AM, van der Bruggen P: Extracellular galectins as controllers of cytokines in hematological cancer. *Blood* 2018, 132:484-491.
 31. Gordon-Alonso M et al.: Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. *Nat Commun* 2017, 8:793
 ** This paper reveals that the extracellular matrix protein galectin-3 binds IFN γ and reduces its diffusion through the tumor matrix in vivo.
 32. Saesen E et al.: Insights into the mechanism by which interferon-gamma basic amino acid clusters mediate protein binding to heparan sulfate. *J Am Chem Soc* 2013, 135:9384-9390.
 33. Collins LE, Troeberg L: Heparan sulfate as a regulator of inflammation and immunity. *J Leukoc Biol* 2019, 105:81-92
 ** This review covers the role of heparin sulfate in regulation of immune responses, including its role in regulating the activity of IFN γ and IL-2 in the extracellular matrix.
 34. Lortat-Jacob H, Baltzer F, Grimaud JA: Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. *J Biol Chem* 1996, 271:16139-16143.
 35. Lighvani AA et al.: T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. *Proc Natl Acad Sci U S A* 2001, 98:15137-15142.

36. Scheper W et al.: Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. *Nat Med* 2019,25:89-94.
37. Lugo-Villarino G et al.: T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. *Proc Natl Acad Sci U S A* 2003, 100:7749-7754.
38. Horiuchi T et al.: Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. *Rheumatology (Oxford)* 2010, 49:1215-1228.
39. Salerno F et al.: Distinct PKC-mediated posttranscriptional events set cytokine production kinetics in CD8(+) T cells. *Proc Natl Acad Sci U S A* 2017, 114:9677-9682.
40. Ebsen H et al.: Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells. *PLoS One* 2013, 8:e76853.
41. van Schie KA et al.: Therapeutic TNF inhibitors can differentially stabilize trimeric TNF by inhibiting monomer exchange. *Sci Rep* 2016, 6:32747.
42. Josephs SF et al.: Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. *J Transl Med* 2018, 16:242.
43. Tufvesson E, Westergren-Thorsson G: Tumour necrosis factor-alpha interacts with biglycan and decorin. *FEBS Lett* 2002, 530:124-128.
44. Alon R et al.: TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein. *J Immunol* 1994, 152:1304-1313.
45. Hershkoviz R, Goldkorn I, Lider O: Tumour necrosis factor-alpha interacts with laminin and functions as a pro-adhesive cytokine. *Immunology* 1995, 85:125-130.
46. Deng M et al.: Shedding of the tumor necrosis factor (TNF) receptor from the surface of hepatocytes during sepsis limits inflammation through cGMP signaling. *Sci Signal* 2015, 8:ra11.
47. Lantz M et al.: Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. *J Clin Invest* 1990, 86:1396-1402.
48. Xanthoulea S et al.: Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. *J Exp Med* 2004, 200:367-376.
49. Pettersson T et al.: Setting up TRAPS. *Ann Med* 2012, 44:109-118.
50. Wrangle JM et al.: IL-2 and beyond in cancer immunotherapy. *J Interferon Cytokine Res* 2018, 38:45-68.
51. Oyler-Yaniv A et al.: A tunable diffusion-consumption mechanism of cytokine propagation enables plasticity in cell-to-cell communication in the immune system. *Immunity* 2017, 46:609-620
 ** Using the combination of mathematical modeling and in vitro and in vivo assays, this study demonstrates that the spatial reach of CD4+ T-cell derived IL-2 in lymph nodes is primarily governed by the local density of IL-2 consuming cells. These data suggest that IL-2 penetration in tissues is primarily regulated by a diffusion-consumption mechanism.
52. Busse D et al.: Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. *Proc Natl Acad Sci U S A* 2010, 107:3058-3063.
53. Damoiseaux J: The IL-2 - IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor. *Clin Immunol* 2020, 218:108515.
54. Sheu BC et al.: A novel role of metalloproteinase in cancer-mediated immunosuppression. *Cancer Res* 2001, 61:237-242.
55. Villarino AV et al.: Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. *J Exp Med* 2007, 204:65-71.
56. Somasundaram R et al.: Collagens serve as an extracellular store of bioactive interleukin 2. *J Biol Chem* 2000,

275:38170-38175.

57. Wrenshall LE, Platt JL: Regulation of T cell homeostasis by heparan sulfate-bound IL-2. *J Immunol* 1999, 163:3793-3800.
58. Magnuson AM et al.: Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types. *Proc Natl Acad Sci U S A* 2018, 115: E10672-E10681.
59. Sun Z et al.: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control. *Nat Commun* 2019,10:3874.
60. Nagarajan A, Malvi P, Wajapeyee N: Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression. *Front Endocrinol (Lausanne)* 2018, 9:483.
61. Cardoso AC et al.: Galectin-3 determines tumor cell adaptive strategies in stressed tumor microenvironments. *Front Oncol* 2016, 6:127.
62. Ruvolo PP: Galectin 3 as a guardian of the tumor microenvironment. *Biochim Biophys Acta* 2016, 1863:427-437.
63. Bates GJ et al.: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. *J Clin Oncol* 2006, 24:5373-5380.
64. Kornfeld JW et al.: Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. *Br J Cancer* 2011, 104:138-145.
65. Gobin E et al.: A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. *BMC Cancer* 2019, 19:581.
66. Altan-Bonnet G, Mukherjee R: Cytokine-mediated communication: a quantitative appraisal of immune complexity. *Nat Rev Immunol* 2019, 19:205-217
** This review provides a comprehensive overview of recent efforts in the systems biology field to quantitatively understand cytokine-mediated communication.

